Page last updated: 2024-08-24

gemcitabine and Myelodysplastic Syndromes

gemcitabine has been researched along with Myelodysplastic Syndromes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C1
De Stefano, V; Leone, G; Mario, AD; Mele, L; Pagano, L1

Trials

1 trial(s) available for gemcitabine and Myelodysplastic Syndromes

ArticleYear
Use of gemcitabine (GEM) in advanced myelodysplastic syndromes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome

2001

Other Studies

1 other study(ies) available for gemcitabine and Myelodysplastic Syndromes

ArticleYear
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
    Pharmacogenetics and genomics, 2015, Volume: 25, Issue:6

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide

2015